Tesamorelin Evidence Guide
Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.
Our Take
Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.
- Best for
- HIV-associated lipodystrophy, visceral fat reduction, GHRH-mediated GH research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 2mg subcutaneous, daily
Benefits and Evidence
- Visceral Adipose Tissue Reduction: Level A, includes human evidence - FDA-approved indication. Phase 3 trials demonstrated approximately 15-18% reduction in trunk fat as measured by CT scan in HIV patients with lipodystrophy after 26 weeks.
- IGF-1 Increase: Level A, includes human evidence - Consistent, significant increases in IGF-1 levels observed across clinical trials, confirming stimulation of the GH/IGF-1 axis.
- Cognitive Function: Level B, includes human evidence - Preliminary data from trials in mild cognitive impairment and Alzheimer disease suggest potential neuroprotective effects, but larger studies are needed.
Side Effects and Warnings
- Injection site reactions (erythema, pruritus)
- Arthralgia
- Peripheral edema
- Myalgia
- Paresthesia
- Elevated IGF-1 levels
- Contraindicated in patients with active malignancy
- Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery
Research Dosage References
- <strong>Subcutaneous injection</strong> - 2 mg - Once daily - FDA-approved dose for HIV-associated lipodystrophy. Injected into the abdomen. Should be administered on an empty stomach or at bedtime.
Mechanism of Action
Tesamorelin acts as an analog of endogenous growth hormone-releasing hormone (GHRH), binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This stimulates the synthesis and pulsatile release of endogenous growth hormone (GH) through the natural hypothalamic-pituitary axis. The released GH then acts on hepatocytes to stimulate IGF-1 production and directly on adipose tissue to promote lipolysis. The lipolytic effect is particularly pronounced in visceral adipose tissue, which is the primary depot affected in HIV-associated lipodystrophy. Unlike exogenous GH administration, tesamorelin preserves the physiological pulsatile pattern of GH secretion and is subject to normal feedback inhibition by IGF-1 and somatostatin. This results in a more favorable safety profile with lower risk of GH-related side effects such as fluid retention, insulin resistance, and carpal tunnel syndrome. The trans-3-hexenoic acid modification at the N-terminus protects the peptide from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), significantly extending its biological half-life compared to native GHRH.
Legal Status
FDA approved (Egrifta). Prescription required. Schedule: Not a controlled substance.
Primary Sources
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Journal of the American Medical Association, 2007.
- Tesamorelin in HIV-associated lipodystrophy: a Phase 3 randomized controlled trial. Annals of Internal Medicine, 2010.
- Tesamorelin effects on cognition in HIV patients with normal cognition, mild cognitive impairment, and dementia. Neurology, 2020.